The gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.
Microba Life Sciences, an Australia-based microbiome measurement technology developer based on research at University of Queensland, floated in a A$30m ($22.5m) initial public offering on the Australian Stock Exchange (ASX) on Monday.
The offering involved the sale of 66.7 million shares at the bottom end of its A$0.45 to A$0.50 range, giving the company a market capitalisation of approximately $93m. Its shares are trading at A$0.42 at the…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
